Novo Stock Rises After Earnings. It's Taking the Weight-Loss Drug Fight to Eli Lilly.
Barrons·2026-05-06 18:12

公司业绩与股价表现 - 诺和诺德股票上涨 原因是公司上调了业绩指引[1] - 业绩指引上调是基于其减肥药产品的强劲表现[1] 核心产品驱动 - 公司的减肥药片表现强劲 成为推动业绩增长的关键动力[1]

Novo Stock Rises After Earnings. It's Taking the Weight-Loss Drug Fight to Eli Lilly. - Reportify